$CBLL

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

TD Cowen maintained a 'Buy' rating on CeriBell (CBLL), raising its price target to $33.00 from $29.00. The company has a market cap of $922.23 million and a GF Score™ of 12/100, indicating financial challenges. Insider activity shows significant selling. CBLL is unprofitable with a P/S ratio of 7.31x, reflecting a premium valuation.

TD Cowen kept a Buy rating on CeriBell with a $33 price target, implying a 39.8% upside from the Oct 1 close of $23.61. The firm cited strong growth potential due to improved sales force productivity and a large market opportunity in EEG devices, including new markets and indications.

TD Cowen raised its price target for Ceribell (CBLL) to $33 from $29, citing strong revenue growth and expanded market opportunities. The company reported $28.1M in Q2 revenue, up 33% YoY, and has beaten sales forecasts since its IPO. Multiple analysts have raised their price targets for Ceribell, reflecting positive sentiment and expectations for continued growth.

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

Chao Xingjuan (President and CEO) sold 20,846 shares of Ceribell, Inc. (CBLL) at $25.03 ($0.52M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

Chao Xingjuan (President and CEO) sold 39,540 shares of Ceribell, Inc. (CBLL) at $24.61 ($0.97M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Chao Xingjuan (President and CEO) sold 6,068 shares of Ceribell, Inc. (CBLL) at $24.02 ($0.15M total) on 2026-08-21.

Blumberg Scott (Chief Financial Officer) sold 34,502 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.86M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.